Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix
about
Systemic therapy for cervical cancer with potentially regulatable oncolytic adenovirusesNeoadjuvant chemotherapy plus surgery versus surgery for cervical cancerNeoadjuvant chemotherapy plus surgery versus surgery for cervical cancerPrognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy.Analysis of the correlation among hypertension, the intake of β-blockers, and overall survival outcome in patients undergoing chemoradiotherapy with inoperable stage III non-small cell lung cancerThe prognostic effect of VEGF expression in squamous cell carcinoma of the cervix treated with radiation therapy alone.Prognostic role of vascular endothelial growth factor in cervical cancer: a meta-analysis.Targeting angiogenesis in advanced cervical cancer.Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers.New molecular mediators in tumor angiogenesis.New molecular targets against cervical cancer.Monoclonal antibodies in gynecological cancer: a critical point of view.Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies.Hypoxia biomarkers in squamous cell carcinoma of the uterine cervix.Role of hypoxia-inducible factor-1α, carbonic anhydrase-IX, glucose transporter-1 and vascular endothelial growth factor associated with lymph node metastasis and recurrence in patients with locally advanced cervical cancerThe relevance of molecular biomarkers in cervical cancer patients treated with radiotherapy.Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trialNo relationship between thymidine phosphorylase (TP, PD-ECGF) expression and hypoxia in carcinoma of the cervixGlucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma?Chemotherapy and molecular targeting therapy for recurrent cervical cancerBreaking down the evidence for bevacizumab in advanced cervical cancer: past, present and future.Nonsurgical management of cervical cancer: locally advanced, recurrent, and metastatic disease, survivorship, and beyond.Targeting important pathways in head and neck cancer: from the bench to the clinic.Development of targeted therapy for squamous cell carcinomas of the head and neck.Cytokines as potential tumour markers.New pharmacotherapy options for cervical cancer.Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology.Prognostic significance of human papillomavirus (HPV) status and expression of selected markers (HER2/neu, EGFR, VEGF, CD34, p63, p53 and Ki67/MIB-1) on outcome after (chemo-) radiotherapy in patients with squamous cell carcinoma of uterine cervix.Bevacizumab for the treatment of cervical cancer.Role of vascular endothelial growth factor in clinically localized prostate cancer treated with radiation therapy.A large-scale retrospective study of the overall survival outcome in nasopharyngeal carcinoma with hypertension in Chinese population.Tumor necrosis factor alpha induces three-dimensional cytomorphologic differentiation of human anaplastic thyroid carcinoma cells through activation of nuclear factor kappaB.A comparison on expression of selected biomarkers between primary lung cancers and matched metastases.Early motor function after local treatment of brain metastases in the motor cortex region with stereotactic radiotherapy/radiosurgery or microsurgical resection: a retrospective study of two consecutive cohorts.SIM2l attenuates resistance to hypoxia and tumor growth by transcriptional suppression of HIF1A in uterine cervical squamous cell carcinoma.Preliminary study of plasma vascular endothelial growth factor (VEGF) during low- and high-dose radiation therapy of dogs with spontaneous tumors.Correlation of quantitative parameters of magnetic resonance perfusion-weighted imaging with vascular endothelial growth factor, microvessel density and hypoxia-inducible factor-1α in nasopharyngeal carcinoma: Evaluation on radiosensitivity study.Modulatory Effects of Chemoradiation on Angiogenic Factors and Laminin in Cervical Cancer: Link with Treatment ResponseGrading of uterine cervical cancer by using the ADC difference value and its correlation with microvascular density and vascular endothelial growth factor.The upregulated expression of vascular endothelial growth factor in surgically treated patients with recurrent/radioresistant cervical cancer of the uterus.
P2860
Q21144267-5C355A5C-85B9-4EE3-A3D5-37BE48192D21Q24202145-42C87BEA-F1BC-4E72-8D24-D67DE9F87B34Q24240630-B24CB631-FAB1-42D1-923A-E04FDF5B70D4Q30849078-66F4CD48-38FB-4254-A548-0C577D873265Q33622701-0DF338EF-EDC2-4D86-AE3C-2F866AE65C27Q33629700-0C78D088-CC35-4CA6-A41C-4A9288121F2AQ33648654-07D6C6C0-DCAB-464E-8124-D955C752457BQ34389368-34A4A2CE-F30E-444B-B577-B1F849989422Q34608643-614ABE50-3AAF-40DA-BC1E-66CC33BFD0F6Q34687698-7A70A33A-A2D9-4AD0-B2FC-ECE1A9272514Q34700859-40769435-CE39-45E7-99A4-E89D8EDBB948Q35659915-070CB0FD-0D88-4FBB-85C7-A0F0065AA16BQ35750289-59DDAB48-B2A1-434A-885B-666B54C9F792Q35821578-9255C2DE-4BC8-4D47-9E08-BDBD7CEF1E1DQ36085682-B6F544D8-BF28-4090-89C5-B8106C9A04A8Q36241881-CD5434E6-8CBD-437B-B793-8CEAFFE61E5CQ36442519-BF842A6F-8AA1-4F43-B896-60B120CCAE30Q36613493-5538EC7E-627A-4CF2-9C12-D8D107F39EB3Q36671784-7F4366B1-4997-4715-AA7E-8A70170B137DQ36897266-B0C2E564-68C0-4CF3-97EA-606F3CF1FD13Q36937771-4B018369-D622-402E-A733-C8FB4C9CC008Q37036792-7E481198-553F-43CE-957E-F2793CBF673CQ37317000-0E2F4DC1-E749-4F4A-AEF4-F640DF3B60BCQ37854706-FE54D53C-5516-4987-9E6E-E3AACC751171Q38089767-99FBDD74-841A-4C56-B9E3-50B681558069Q38160897-3759B289-D1DA-4A20-840B-781BF069A269Q38373926-5E19041A-DFE1-492B-A130-ECAD06C5FB78Q38395430-4066B990-91E6-4143-AF53-35168953CD67Q38706483-1C2727D1-BC60-4676-85F4-A0E4F297D3FBQ42757412-59192A11-E3C0-46CC-B1E8-F19BA1CBC04DQ43534303-76101E87-339B-414D-A898-161E636451A3Q44197090-2E3CD0CE-6E54-4441-90B5-CF208E808496Q46642129-9DFD21E5-DC68-4D8B-934F-10E44009A545Q46925673-25285E11-496E-47C8-B8D5-877E27ED1A25Q47150172-AA24DDA0-EFC6-47E4-A87D-DE6E6ABAB1E1Q47335169-D2EAC0D5-21E3-4C22-82B7-D98F3AAA5F0AQ48092745-9E069BCB-9DC6-4C3A-9306-911A1D5871FEQ49363771-6B996A08-1FF1-4E72-9488-5DBDCE98B0C9Q51326019-EA96B69D-3437-4DB7-A172-2CBA2E47EA7BQ55287714-4B316B09-0741-4C9C-B955-96A82ACC63DA
P2860
Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Vascular endothelial growth fa ...... vanced carcinoma of the cervix
@ast
Vascular endothelial growth fa ...... vanced carcinoma of the cervix
@en
type
label
Vascular endothelial growth fa ...... vanced carcinoma of the cervix
@ast
Vascular endothelial growth fa ...... vanced carcinoma of the cervix
@en
prefLabel
Vascular endothelial growth fa ...... vanced carcinoma of the cervix
@ast
Vascular endothelial growth fa ...... vanced carcinoma of the cervix
@en
P2093
P2860
P356
P1476
Vascular endothelial growth fa ...... vanced carcinoma of the cervix
@en
P2093
P2860
P2888
P304
P356
10.1054/BJOC.2000.1319
P407
P577
2000-09-01T00:00:00Z
P5875
P6179
1024695013